Get the Stockscreener App
113.56
3.45%
-4.06
After Hours:
113.60
0.04
+0.04%
Rhythm Pharmaceuticals Inc stock is traded at $113.56, with a volume of 1.73M.
It is down -3.45% in the last 24 hours and up +15.97% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$117.62
Open:
$119.58
24h Volume:
1.73M
Relative Volume:
2.42
Market Cap:
$7.58B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-40.41
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
+8.57%
1M Performance:
+15.97%
6M Performance:
+80.20%
1Y Performance:
+103.95%
1-Day Range:
$109.59
$119.58
1-Week Range:
$99.96
$122.20
52-Week Range:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
113.56 | 7.85B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $167.00 at Citizens Jmp - MarketBeat
Rhythm advances lead asset into late-stage trial in Prader-Willi syndrome - MSN
Alkeon Capital Management LLC Grows Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Citizens Maintains Rhythm Pharmaceuticals (RYTM) Market Outperform Recommendation - Nasdaq
Canaccord Genuity Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
RYTM Stock: Canaccord Genuity Raises Price Target to $141, Maint - GuruFocus
Goldman Sachs Raises Price Target for RYTM to $157, Maintains Bu - GuruFocus
Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential - MSN
Canaccord Genuity raises Rhythm Pharmaceuticals stock price target on positive PWS data - Investing.com Canada
Rhythm Pharma Surprises With Encouraging PWS Drug Trial Results - Finimize
Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says - marketscreener.com
RYTM Analyst Rating Update: Citizens Raises Price Target to $167 - GuruFocus
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $150 From $129, Keeps Overweight Rating - marketscreener.com
Rhythm Pharmaceuticals stock price target raised to $167 at Citizens By Investing.com - Investing.com Canada
Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals - TipRanks
Rhythm Pharmaceuticals stock price target raised to $167 at Citizens - Investing.com India
Rhythm Pharmaceuticals stock jumps as Goldman Sachs raises price target on PWS study - Investing.com Canada
Rhythm Pharmaceuticals (RYTM): Reassessing Valuation After Positive Prader-Willi Data and Phase 3 Trial Plans - Yahoo Finance
Is It Too Late to Invest in Rhythm Pharmaceuticals After Its 2025 Rally? - Yahoo Finance
Growth or Bubble? Exploring Rhythm’s Recent Surge - StocksToTrade
Rhythm Pharmaceuticals stock hits all-time high at 116.08 USD By Investing.com - Investing.com Canada
Needham Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
Rhythm Pharma Soars with Buy Rating and Optimistic Trials - StocksToTrade
Rhythm Pharmaceuticals’ Stock Surge: Buy Now? - timothysykes.com
Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster (RYTM) - Seeking Alpha
Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win - Investor's Business Daily
Rhythm Pharmaceuticals reports positive results in Prader-Willi trial By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals stock holds Buy rating at TD Cowen on PWS trial data - Investing.com Canada
Rhythm Pharmaceuticals Surges: Strategic Moves Fuel Market Buzz - timothysykes.com
Needham Raises Price Target for Rhythm Pharmaceuticals (RYTM) to $145 | RYTM Stock News - GuruFocus
Morgan Stanley raises Rhythm Pharmaceuticals stock price target to $150 By Investing.com - Investing.com UK
Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise - Benzinga
Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 12-Month HighHere's Why - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 1-Year HighWhat's Next? - MarketBeat
Rhythm Pharmaceuticals stock rises after positive study data for setmelanotide in treating genetic disorder - MSN
RYTM: Setmelanotide showed promising BMI and hyperphagia improvements in PWS, supporting phase 3 plans - TradingView
Rhythm Pharmaceuticals (RYTM) Soars Over 15% in Market Rally - GuruFocus
Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder - Stocktwits
Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday - Benzinga
Rhythm Pharmaceuticals (RYTM) Climbs Over 11% - GuruFocus
Citi Initiates Buy Coverage on Rhythm Pharmaceuticals with Price Target Set for Growth - timothysykes.com
Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook - ts2.tech
Rhythm Pharmaceuticals Stock Climbs on Positive Trial News - TipRanks
Rhythm Pharmaceuticals stock soars after positive trial results By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals stock soars after positive trial results - Investing.com India
Rhythm Pharmaceuticals stock hits all-time high at 116.08 USD - Investing.com
Rhythm Pharma rises on positive mid-stage data for rare disease therapy - TradingView — Track All Markets
Rhythm Pharmaceuticals reports positive results in Prader-Willi trial - Investing.com
Rhythm Pharmaceuticals Announces Preliminary Phase 2 Trial Results for Setmelanotide in PWS - TradingView — Track All Markets
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome - The Manila Times
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):